Acelat en es it fr

Acelat Brand names, Acelat Analogs

Acelat Brand Names Mixture

  • No information avaliable

Acelat Chemical_Formula


Acelat RX_link

Acelat fda sheet

Acelat FDA

Acelat msds (material safety sheet)

Acelat MSDS

Acelat Synthesis Reference

No information avaliable

Acelat Molecular Weight

514.617 g/mol

Acelat Melting Point


Acelat H2O Solubility

Practically insoluble

Acelat State


Acelat LogP


Acelat Dosage Forms


Acelat Indication

For the treatment of hypertension.

Acelat Pharmacology

Telmisartan is an orally active nonpeptide angiotensin II antagonist that acts on the AT1 receptor subtype. New studies suggest that telmisartan may also have PPARγ agonistic properties that could potentially confer beneficial metabolic effects. This observation is currently being explored in clinical trials. Angiotensin II is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II). Angiotensin II is the principal pressor agent of the renin-angiotensin system, with effects that include vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium. Telmisartan works by blocking the vasoconstrictor and aldosterone secretory effects of angiotensin II.

Acelat Absorption

Absolute bioavailability depends on dosage. Food slightly decreases the bioavailability (a decrease of about 6% is seen when the 40-mg dose is administered with food).

Acelat side effects and Toxicity

Intravenous LD50 in rats is 150-200 mg/kg in males and 200 to 250 mg/kg in females. Acute oral toxicity is low: no deaths and no changes occurred in rats or dogs at 2000 mg/kg, the highest dose tested. Limited data are available with regard to overdosage in humans. The most likely manifestations of overdosage with telmisartan would be hypotension, dizziness and tachycardia; bradycardia could occur from parasympathetic (vagal) stimulation.

Acelat Patient Information

Acelat Organisms Affected

Humans and other mammals